University of Kansas Medical Center, Kansas City, KS
Tara L. Lin , Geoffrey L. Uy , Roland B. Walter , Heng Zou , Qi Wang , Stefan Faderl , Ronald Cheung , Vinod A. Pullarkat
Background: CPX-351 (Vyxeos; daunorubicin and cytarabine liposome for injection) is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In a phase 3 study in patients (pts) aged 60-75 y with newly diagnosed high-risk/secondary AML who were fit for IC, CPX-351 significantly improved median survival versus 7+3 cytarabine/daunorubicin and had a comparable safety profile. However, it may not be appropriate to administer CPX-351 at the label dosage in pts unfit for IC. Venetoclax, a BCL-2 inhibitor, has clinical efficacy in combination with low-dose cytarabine in AML pts unfit for IC, and preclinical data suggest a rationale for combining CPX-351 and venetoclax. This study thus evaluates CPX-351 LIT in combination with venetoclax in AML pts unfit for IC. Methods: This is an open-label, multicenter, 2-part, phase 1b study (NCT04038437) to determine the maximum tolerated dose (MTD) and evaluate the safety, efficacy, and pharmacokinetics of CPX-351 LIT plus venetoclax. Key eligibility criteria are shown in the Table. In the dose-escalation phase (3+3 design), up to 24 pts will receive CPX-351 (dose levels: 20, 40, 60, and 75 units/m2) on Days 1 and 3 plus venetoclax 400 mg on Days 2-21 of each cycle to determine the MTD, with each dose escalation confirmed by a safety assessment committee. Pts who achieve complete or partial remission after 1 or 2 cycles may receive up to 4 similar cycles of CPX-351 plus venetoclax. In the expansion phase, an additional 20 pts will be treated at the MTD. All pts are assessed for response by morphology and minimal residual disease testing, and are monitored for safety (until 1 month after end of treatment) and survival (up to 1 year after start of treatment). The study is ongoing and actively enrolling pts. Clinical trial information: NCT04038437.
≥18 y |
Histologically confirmed (per WHO criteria) newly diagnosed AML |
Considered unfit for IC o ≥75 yOR o 18-74 y and ≥1 of the following criteria: ECOG PS 2-3 History of congestive heart failure requiring treatment or LVEF ≤50% Diffusing capacity of the lung for carbon monoxide ≤65% or forced expiratory volume in 1 sec ≤65% Creatinine clearance ≥30 to < 45 mL/min Moderate hepatic impairment with total bilirubin > 1.5 to ≤3.0 × upper limit of normal Other comorbidity incompatible with conventional IC |
No CNS involvement |
No antecedent myeloproliferative neoplasms |
No favorable-risk cytogenetics (per NCCN guidelines) |
No prior AML treatment except hydroxyurea |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Geoffrey L. Uy
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Zev A. Wainberg